Dr Rami Komrokji discusses the link between TIM-3 expression and immune dysfunction in HR-MDS and AML
Visit TIM3.com for more myeloid disease expert videos like this one.
Disease Education
An Understanding of Immuno-Therapeutic Approaches, Such as Immuno-Myeloid Therapy, Is Emerging
Graphic Science Series: TIM-3, an Immuno-Myeloid Regulator in MDS and AML
Explore the role of TIM-3 in dysregulating immune responses in MDS & AML
Interested in seeing what your colleagues think about some hot issues in myeloid disease? Take this poll and see the results. It’s quick and maybe even a little fun.
Download our brochure to learn about the role of TIM-3 expression plays in immune dysfunction in HR-MDS and AML.
AML = Acute myeloid leukemia; HR-MDS = Higher risk Myelodysplastic syndrome; MDS = Myelodysplastic syndrome.
The Potential of Immuno-Myeloid Therapies Is Emerging
Graphic Science Series: TIM-3 Illustrated
Learn about Novartis research targeting TIM-3 with investigational drug, sabatolimab, in MDS and AML.
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA is based on in vitro/in vivo data. Clinical benefit is unknown.
AML = Acute myeloid leukemia; HR-MDS = Higher risk Myelodysplastic syndrome; MDS = Myelodysplastic syndrome.
Explore Clinical Trials
Explore Clinical Trials
IR MDS, HR MDS, & VHR MDS
STIMULUS-MDS-US
Sabatolimba + HMA in Patients with IR-, HR-, or VHR-MDS
IR MDS, HR MDS, & VHR MDS
STIMULUS-MDS2
Sabatolimba + Azacitidine in Patients with IR-, HR-, or VHR-MDS
HR MDS & VHR MDS
STIMULUS-MDS3
Sabatolimab + Azacitidine/Venetoclax in Patients with HR- or VHR-MDS
LR MDS
NCT04810611
Select Drug Combinations in Patients with LR-MDS
De novo AML
STIMULUS-AML1
Sabatolimab + Azacitidine / Venetoclax in Patients with AML
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Explore Compounds
Explore Compounds
Spartalizumab (PDR001)
PD-1–targeting monoclonal antibody
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA is based on in vitro/in vivo data. Clinical benefit is unknown.
MDS = Myelodysplastic syndrome; AML = Acute myeloid leukemia
